This company listing is no longer active
Oncternal Therapeutics Past Earnings Performance
Past criteria checks 0/6
Oncternal Therapeutics's earnings have been declining at an average annual rate of -10.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 16.1% per year.
Key information
-10.7%
Earnings growth rate
60.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -16.1% |
| Return on equity | -378.0% |
| Net Margin | -1,600.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Revenue & Expenses Breakdown
How Oncternal Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -35 | 12 | 0 |
| 30 Jun 24 | 2 | -36 | 13 | -1 |
| 31 Mar 24 | 1 | -36 | 13 | 0 |
| 31 Dec 23 | 1 | -39 | 13 | 0 |
| 30 Sep 23 | 1 | -42 | 13 | 0 |
| 30 Jun 23 | 1 | -43 | 13 | 2 |
| 31 Mar 23 | 1 | -46 | 13 | 0 |
| 31 Dec 22 | 1 | -44 | 13 | 0 |
| 30 Sep 22 | 2 | -41 | 13 | 0 |
| 30 Jun 22 | 4 | -39 | 12 | 0 |
| 31 Mar 22 | 4 | -35 | 12 | 0 |
| 31 Dec 21 | 4 | -31 | 12 | 0 |
| 30 Sep 21 | 5 | -26 | 10 | 0 |
| 30 Jun 21 | 4 | -21 | 10 | 0 |
| 31 Mar 21 | 4 | -18 | 9 | 0 |
| 31 Dec 20 | 3 | -17 | 8 | 0 |
| 30 Sep 20 | 3 | -19 | 9 | 0 |
| 30 Jun 20 | 2 | -19 | 10 | 0 |
| 31 Mar 20 | 3 | -37 | 9 | 0 |
| 31 Dec 19 | 2 | -34 | 7 | 0 |
| 30 Sep 19 | 2 | -31 | 5 | 0 |
| 30 Jun 19 | 2 | -28 | 3 | 0 |
| 31 Mar 19 | 3 | -7 | 2 | 0 |
| 31 Dec 18 | 3 | -7 | 2 | 0 |
| 31 Dec 17 | 2 | -10 | 3 | 0 |
Quality Earnings: ONCT is currently unprofitable.
Growing Profit Margin: ONCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONCT is unprofitable, and losses have increased over the past 5 years at a rate of 10.7% per year.
Accelerating Growth: Unable to compare ONCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ONCT has a negative Return on Equity (-377.95%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/04 18:05 |
| End of Day Share Price | 2024/12/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncternal Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kaveri Pohlman | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Carl Byrnes | Northland Capital Markets |